Blueprint Medicines
MA - Cambridge
Biotechnology7 H-1B visas (FY2023)Focus: Small Molecule Discovery
Blueprint Medicines is a life sciences company focused on Small Molecule Discovery.
OncologyWomen's HealthDermatology
Funding Stage
PUBLIC
Open Jobs
1
Products & Portfolio (3)
AYVAKIT
avapritinib
Peak
SMORAL · TABLET
Tyrosine Kinase Inhibitors
metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutationleukemia
2020
0
GAVRETO
pralsetinib
Peak
SMORAL · CAPSULE
2020
30
LILETTA
levonorgestrel
Peak
INTRAUTERINE · SYSTEM
demonstrated. Studies of LNG-releasing IUSs suggest several mechanisms for pregnancy prevention: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm mobility and function (capacitation), and alteration of the endometrium.
pregnancy for up to 8 yearsheavy menstrual bleeding for up to 5 years in patients
2015
0
Pipeline & Clinical Trials
Screening
Systemic Mast Cell ActivationClinical Trials (1)
NCT04811365(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
N/Apralsetinib
Non-Small Cell Lung CancerClinical Trials (1)
NCT04204928Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
N/AScreening
Clonal Mast Cell DiseaseClinical Trials (1)
NCT07143669Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
N/AMast Cell Connect: A Registry for Patients With Mastocytosis
MastocytosisClinical Trials (1)
NCT02620254Mast Cell Connect: A Registry for Patients With Mastocytosis
N/ARetrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients Wi
Advanced Systemic MastocytosisClinical Trials (1)
NCT04695431Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
N/AThere are no interventions in this study. All participants complete online surveys.
Lung Cancer PatientsPatient treated by Avapritinib in real life
GISTClinical Trials (1)
NCT04927260French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
N/AAvapritinib
GISTClinical Trials (1)
NCT03862885Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
N/AAvapritinib
Solid TumorsClinical Trials (1)
NCT04714086Expanded Access Program for Avapritinib
N/AAvapritinib
Indolent Systemic MastocytosisClinical Trials (1)
NCT07255638A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
N/AN/A
Clinical Trials (1)
NCT02380222Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
N/AExternal Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy
RET-fusion Non Small Cell Lung CancerClinical Trials (1)
NCT04697446External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
N/AAn Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Indolent Systemic MastocytosisClinical Trials (1)
NCT07264959An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
N/APhase 1
Clinical Trials (1)
NCT06327685Avapritinib With Decitabine in Patients With SM-AHN
Phase 1BLU-701
Lung NeoplasmClinical Trials (1)
NCT05153408(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Phase 1BLU-782
Healthy VolunteersClinical Trials (1)
NCT03858075Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
Phase 1Avapritinib
Gastrointestinal Stromal Tumors (GIST)Clinical Trials (1)
NCT02508532(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05609942Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Phase 1BLU-945
Lung NeoplasmsClinical Trials (1)
NCT04862780(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Phase 1BLU-451
Lung Neoplasm MalignantClinical Trials (1)
NCT05241873(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Phase 1Avapritinib
Gastrointestinal Stromal TumorsClinical Trials (1)
NCT04908176A Drug-drug Interaction Study of Avapritinib and Midazolam
Phase 1Avapritinib
Aggressive Systemic MastocytosisClinical Trials (1)
NCT02561988(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Phase 1Elenestinib
Healthy ParticipantsClinical Trials (1)
NCT07388511A Study of Elenestinib in Healthy Adult Female Participants
Phase 1BLU-222
Advanced Solid TumorsClinical Trials (1)
NCT05252416(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1BLU-808
Healthy ParticipantsClinical Trials (1)
NCT06948032Study of BLU-808 in Healthy Adult Participants
Phase 1Fisogatinib
Hepatocellular Carcinoma (HCC)Clinical Trials (1)
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Phase 1avapritinib
Solid Tumor, Unspecified, ChildClinical Trials (1)
NCT04773782A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT04254939A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
Phase 1/2Phase Ib: Fisogatinib
Hepatocellular CarcinomaClinical Trials (1)
NCT04194801A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
Phase 1/2Avapritinib
Indolent Systemic MastocytosisClinical Trials (1)
NCT03731260(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Phase 2BLU-808
Chronic Inducible UrticariaClinical Trials (1)
NCT06931405Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Phase 2BLU-808
Allergic RhinoconjunctivitisClinical Trials (1)
NCT06922448Study of BLU-808 in Allergic Rhinoconjunctivitis
Phase 2Avapritinib
Advanced Systemic MastocytosisClinical Trials (1)
NCT03580655(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Phase 2Elenestinib
Indolent Systemic MastocytosisClinical Trials (1)
NCT04910685(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Phase 2/3avapritinib
GISTClinical Trials (1)
NCT03465722(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Phase 3Avapritinib
Gastrointestinal Stromal TumorsClinical Trials (1)
NCT04825574Study for Patients Previously Treated in Avapritinib Clinical Trials
Phase 4Avapritinib
Mastocytosis, SystemicClinical Trials (1)
NCT06748001Avapritinib Rollover Study
Phase 4Open Jobs (1)
Interview Prep Quick Facts
Portfolio: 3 approved products, 36 clinical trials
Top TAs: Oncology, Respiratory, Women's Health
H-1B (2023): 7 approvals
Open Roles: 1 active job
Portfolio Health
Peak3 (100%)
3 total products
Therapeutic Area Focus
Marketed
Pipeline
Hiring Trend
Stable
1
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
7
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub